These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 10702217)

  • 1. Probiotic therapy with E. coli for ulcerative colitis: take the good with the bad.
    Faubion WA; Sandborn WJ
    Gastroenterology; 2000 Mar; 118(3):630-1. PubMed ID: 10702217
    [No Abstract]   [Full Text] [Related]  

  • 2. [Maintaining remission of ulcerative colitis with the probiotic Escherichia Coli Nissle 1917 is as effective as with standard mesalazine].
    Adam B; Liebregts T; Holtmann G
    Z Gastroenterol; 2006 Mar; 44(3):267-9. PubMed ID: 16514573
    [No Abstract]   [Full Text] [Related]  

  • 3. [Probiotics for prevention of ulcerative colitis recurrence: alternative medicine added to standard treatment?].
    Folwaczny C
    Z Gastroenterol; 2000 Jun; 38(6):547-50. PubMed ID: 10923365
    [No Abstract]   [Full Text] [Related]  

  • 4. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial.
    Rembacken BJ; Snelling AM; Hawkey PM; Chalmers DM; Axon AT
    Lancet; 1999 Aug; 354(9179):635-9. PubMed ID: 10466665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine.
    Kruis W; Fric P; Pokrotnieks J; Lukás M; Fixa B; Kascák M; Kamm MA; Weismueller J; Beglinger C; Stolte M; Wolff C; Schulze J
    Gut; 2004 Nov; 53(11):1617-23. PubMed ID: 15479682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Role of prebiotics and probiotics in therapeutic management of cryptogenetic inflammatory bowel disease].
    Marteau P; Seksik P
    Gastroenterol Clin Biol; 2001 Sep; 25(2 Pt 2):C94-7. PubMed ID: 11787388
    [No Abstract]   [Full Text] [Related]  

  • 7. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis.
    Kruis W; Schütz E; Fric P; Fixa B; Judmaier G; Stolte M
    Aliment Pharmacol Ther; 1997 Oct; 11(5):853-8. PubMed ID: 9354192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Ulcerative colitis].
    Felley C; Michetti P
    Rev Med Suisse Romande; 2002 Sep; 122(9):441-4. PubMed ID: 12422474
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy of a symbiotic product during clinical relapse of ulcerative colitis.
    Guslandi M
    J Clin Gastroenterol; 2011; 45(5):475-6. PubMed ID: 21336142
    [No Abstract]   [Full Text] [Related]  

  • 10. Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update.
    Scaldaferri F; Gerardi V; Mangiola F; Lopetuso LR; Pizzoferrato M; Petito V; Papa A; Stojanovic J; Poscia A; Cammarota G; Gasbarrini A
    World J Gastroenterol; 2016 Jun; 22(24):5505-11. PubMed ID: 27350728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Contemporary views on non-specific ulcerative colitis and conservative methods of its treatment ].
    Bakulin IG; Stanke DA
    Voen Med Zh; 2008 Nov; 329(11):50-4. PubMed ID: 19186525
    [No Abstract]   [Full Text] [Related]  

  • 12. Survival of the probiotic Escherichia coli Nissle 1917 (EcN) in the gastrointestinal tract given in combination with oral mesalamine to healthy volunteers.
    Joeres-Nguyen-Xuan TH; Boehm SK; Joeres L; Schulze J; Kruis W
    Inflamm Bowel Dis; 2010 Feb; 16(2):256-62. PubMed ID: 19637333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The long-term effects of probiotics in the therapy of ulcerative colitis: A clinical study.
    Palumbo VD; Romeo M; Marino Gammazza A; Carini F; Damiani P; Damiano G; Buscemi S; Lo Monte AI; Gerges-Geagea A; Jurjus A; Tomasello G
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2016 Sep; 160(3):372-7. PubMed ID: 27623957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study.
    Henker J; Müller S; Laass MW; Schreiner A; Schulze J
    Z Gastroenterol; 2008 Sep; 46(9):874-5. PubMed ID: 18810672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Probiotics in chronic inflammatory bowel disease].
    Böhm S; Kruis W
    MMW Fortschr Med; 2006 Aug; 148(35-36):30-4. PubMed ID: 16995360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VSL#3 and remission in active ulcerative colitis: larger studies required.
    Jackson EL; Hamlin PJ; Ford AC
    Am J Gastroenterol; 2011 Mar; 106(3):547; author reply 547-8. PubMed ID: 21378771
    [No Abstract]   [Full Text] [Related]  

  • 17. [Ulcerative colitis. Complementary therapies].
    Matthes H; Moser G; Jantschek G
    Z Gastroenterol; 2004 Sep; 42(9):1031-2. PubMed ID: 15455282
    [No Abstract]   [Full Text] [Related]  

  • 18. Escherichia coli for ulcerative colitis.
    Langman MJ; Allan RN
    Lancet; 1999 Dec; 354(9194):2000-1. PubMed ID: 10622327
    [No Abstract]   [Full Text] [Related]  

  • 19. Pyostomatitis vegetans: A clinical marker of silent ulcerative colitis.
    Markiewicz M; Suresh L; Margarone J; Aguirre A; Brass C
    J Oral Maxillofac Surg; 2007 Feb; 65(2):346-8. PubMed ID: 17236948
    [No Abstract]   [Full Text] [Related]  

  • 20. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management.
    Harbord M; Eliakim R; Bettenworth D; Karmiris K; Katsanos K; Kopylov U; Kucharzik T; Molnár T; Raine T; Sebastian S; de Sousa HT; Dignass A; Carbonnel F;
    J Crohns Colitis; 2017 Jul; 11(7):769-784. PubMed ID: 28513805
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.